Ensom i Depression
Effekter af Ensomhed i Behandlingen af Depression
Formålet med denne prospektive undersøgelse er at få en bedre forståelse af sammenhængen mellem ensomhed og depression i den indlagte psykiatriske behandling af depression. Den har til formål at besvare:
Drager ensomme og ikke-ensomme personer samme fordel af indlagt depressionbehandling? Er ensomhed en klinisk relevant faktor i indlagt behandling af depression? Hvad er de underliggende biopsykosociale mekanismer?
Deltagerne vil blive bedt om at udføre nogle
- selvrapporteringsspørgeskemaer
- klinisk interview
- biosampling (blod, spyt, afføring) ved tre hovedmålingstidspunkter (1. start af indlagt behandling, 2. udskrivningsdagen, 3. tre måneder efter udskrivning).
Studieoversigt
Status
Status
Betingelser
Betingelser
Detaljeret beskrivelse
Ensomhed og depression er udbredte og alvorligt invaliderende helbredstilstande. Det er især værd at bemærke, at ensomhed og depression er tæt forbundet, hvor individer, der lider af depression, er særligt udsatte for ensomhed. Der vides dog kun lidt om den kliniske betydning af ensomhed i behandlingen af depression og de biopsykosociale mekanismer, der ligger til grund for denne sammenhæng.
For at undersøge den kliniske relevans af samspillet mellem ensomhed og depression vil der blive anvendt et prospektivt, ikke-interventionelt longitudinelt design. Studiet vil blive udført på universitetssygehuset og det kommunale sygehus i Erlangen, Tyskland. Hver patient, der indlægges på sygehuset med depressive symptomer, er berettiget til screening i henhold til inklusions- og eksklusionskriterierne. Tre hovedmålepunkter (T0, T1 og T2) og korte mellemliggende målinger udført med to ugers mellemrum (t0.1 til t0.X og t1.1-t1.6) vil blive anvendt. Efter screening og kliniske interviews vil deltagerne gennemføre baseline-målingerne (T0). Derefter vil hver deltager følge en individuel periode svarende til varigheden af den specifikke patients indlæggelsesperiode på klinikken, indtil den anden måling indhentes (T1). Opfølgning vil finde sted tre måneder efter T1.
Da effektstørrelserne for interaktionen mellem ensomhed og depression i en klinisk population i øjeblikket er ukendte, blev stikprøvestørrelsen for dette studie bestemt ud fra overvejelser om praktisk gennemførlighed og resultaternes generaliserbarhed til populationen, samt statistisk plausibilitet.
For at sikre resultaternes eksterne validitet er det vigtigt, at både svært ensomme depressive patienter og mindre ensomme depressive patienter, samt forskellige sygdomsforløb og patientkarakteristika (f.eks. alder, køn og antal komorbiditeter), kan identificeres. En stikprøvestørrelse på cirka 200 deltagere forventes at sikre tilstrækkelig heterogenitet. Denne stikprøvestørrelse er praktisk gennemførlig på grund af det faktum, at selv ved at overveje en inklusionsrate på 50% og en frafald på 30% for den primære diagnose af depression på universitetssygehuset og det kommunale sygehus i Erlangen, overstiger rekrutteringspotentialet klart det målrettede antal tilfælde inden for en estimeret periode på to år.
Uden viden om, hvilket målt niveau af ensomhed ved baseline repræsenterer et stærkt niveau af ensomhed, og hvilket målt niveau repræsenterer et svagt niveau af ensomhed i en depressiv patientpopulation, vil der blive udført en medianopdeling af ensomhed ved baseline for at beregne den statistiske signifikans af interaktionen mellem ensomhed og depression i indlæggelses- og opfølgningsforløbet (T0, T1 og T2). For at påvise en signifikant interaktionseffekt af en blandet variansanalyse (ANOVA), når man overvejer en α-fejl på 0,05, en styrke på 0,9 (1-β fejlsandsynlighed) og en korrelationsværdi blandt gentagne målinger på 0,5 for de grupper, der er defineret som højt ensomme og let ensomme grupper, blev antallet af tilfælde beregnet ved hjælp af G*Power Version 3.1.9.7. Forudsat en lille effektstørrelse (f= 0,10), ville den ønskede stikprøvestørrelse blive bestemt til n= 214 individer; desuden, forudsat en medium effektstørrelse (f= 0,25), ville stikprøvestørrelsen være n= 36 individer. Dette indikerer, at der er statistisk plausibilitet for at påvise interaktionseffekter mellem ensomhed og depression med det målrettede antal tilfælde.
Berettigelsesscreening og klinisk diagnostisk screening sammen med interviews udføres af studielæger. Depression vurderes under et klinisk interview (MADRS) af patientens behandlingsteam, som også bestemmer, hvornår patienten vil blive udskrevet fra sygehuset. Alle selvrapporterede vurderinger indsamles af patienterne selv ved hjælp af REDCap onlineundersøgelsesapplikationen. Biosampling vil udelukkende blive udført blandt deltagere rekrutteret på universitetssygehuset for at sikre metodisk konsistent og hurtig behandling. Rutinemæssige kliniske data udvindes primært fra kliniske dokumentationssystemer og konsolideres før analyse (svarende til andre datakilder).
Da studiedesignet ikke tillader definitive kausale konklusioner at fastslå vedrørende effekternes retning, forventes resultaterne at give værdifuld indsigt og relevante implikationer. Især kan følgende indsigter opnås: (1) en rapport om, hvorvidt mere eller mindre ensomme patienter får lige stor gavn af indlagt multimodal depressionbehandling; (2) indsigt i ændringer i ensomhed under og efter depressionbehandling; (3) vigtige fund vedrørende de delte og ikke-delte biopsykosociale mekanismer, der ligger til grund for ensomhed og depression; og (4) effekterne af ensomhed og depression med hensyn til sekundære resultater, herunder livskvalitet og selvmordstanker.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Franziska Sonnauer, Dr. med., M.Sc.
- Telefonnummer: 00499131-8534597
- E-mail: franziska.sonnauer@uk-erlangen.de
Undersøgelse Kontakt Backup
- Navn: Franca Fries, Dr. med.
- Telefonnummer: 004991317530
- E-mail: Franca.Fries@bezirkskliniken-mfr.de
Studiesteder
-
-
Bavaria
-
Erlangen, Bavaria, Tyskland, 91054
- Rekruttering
- Friedrich-Alexander-Universität Erlangen-Nürnberg
-
Kontakt:
- Franziska Sonnauer, Dr. med.
- Telefonnummer: 00499131-8534597
- E-mail: einsamkeit-depression.ps@uk-erlangen.de
-
Ledende efterforsker:
- Franziska Sonnauer, Dr. med.
-
Underforsker:
- Johannes Kornhuber, Prof. Dr. med.
-
Underforsker:
- Daniel Blasko, Dr. med.
-
Underforsker:
- Ilka Scheer
-
Erlangen, Bavaria, Tyskland, 91056
- Ikke rekrutterer endnu
- Bezirkskliniken Mittelfranken, Clinic for Psychiatry, Addiction, Psychotherapie and Psychosomatic Medicine
-
Kontakt:
- Franca Laura Fries, Dr. med.
- Telefonnummer: 004991317535353
- E-mail: Franca.Fries@bezirkskliniken-mfr.de
-
Kontakt:
- Maksym Druzenko
- Telefonnummer: 004991317535353
- E-mail: Maksym.Druzenko@bezirkskliniken-mfr.de
-
Ledende efterforsker:
- Franca Laura Fries, Dr. med.
-
Underforsker:
- Maksym Druzenko
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inklusionskriterier:
- primær diagnose af depression ifølge ICD-10 (F32 eller F33), diagnosticeret af en læge eller klinisk psykolog i forbindelse med M.I.N.I. Mini-International Neuropsychiatric Interview diagnostiske værktøjer
- indlæggelse på valgfri eller akut basis på et af de to psykiatriske klinikker; - alder over 18 år
- tilstrækkelig forståelse af talt og skrevet tysk
- informet frivilligt samtykke
Eksklusionskriterier:
- nuværende manglende evne til at give samtykke (f.eks. udtalte psykotiske symptomer, stuporøst depressivt syndrom og tankeforstyrrelser med selvmordstanker)
- tidligere deltagelse i studiet
- graviditet eller amning
- indlæggelsesforløb på mindre end 7 dage, selvom patienterne oprindeligt opfyldte inklusionskriterierne.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Depression (symptom severity)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Montgomery-Åsberg Depression Rating Scale (MADRS) (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Loneliness
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
3 Item UCLA Loneliness Scale (3-Item UCLA) (3 items, each item rated 1-3 points, minimum 3 points, maximum 9 points, higher scores indicate greater loneliness)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Depression
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Patient Health Questionnaire, 9-Item Depression Scale (PHQ-9) (9 Items, each item rated 0-4 points, minimum 0 points, maximum 27 points, higher scores indicate greater severity of depression)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Loneliness
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
6-Item short scales for Loneliness, De Jong Gierveld Loneliness Scale (6-Item DJGLS) (6 Items, each item rated 1-3 points, before the total score is calculated, the items are dichotomized, thus resulting in a sum score ranging from 0 to 6, wherein scores of 0-1 indicate no loneliness, 2-4 indicate moderate loneliness, and 5-6 indicate severe loneliness)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Social Support
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Fragebogen zur Sozialen Unterstützung (F-SoZ-U 14) (14 Item shortend form, each item rated 0-4 points, minimum 0 points, maximum 56 points, higher total scores indicating higher levels of perceived social support)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Inpatient treatment duration
Tidsramme: Baseline/T0 (day 1 of inpatient stay) to T1 (end of inpatient stay, normally 7 up to 50 weeks).
|
in days
|
Baseline/T0 (day 1 of inpatient stay) to T1 (end of inpatient stay, normally 7 up to 50 weeks).
|
|
Quality of life in self-report
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
World Health Organization-Five Well-Being Index (WHO-5) (5 Items, each item rated 0-5 points, minimum 0 points, maximum 25 points, the total score (0-25) is transformed to a scale ranging from 0 to 100, with scores ≤50 indicating diminished well-being and higher scores representing higher well-beeing)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Social Network measure (newly designed for this study)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
As there is no culture and language adapted version of a social network indice available an adapted and German-translated version is used to capture participants' social interaction partners during the prior two weeks. The questionnaire was newly developed, with item content informed by existing validated scales (Cohen Social Network Index (SNI), Lubben Social Network Scale (LSNS), Berkman - Social Network/Integration). Via the use of a yes/no response format, participants indicated whether they had personal or telephone contact with each of the following: (1) spouse or partner, (2) own children, (3) parents or parent-like figures, (4) other relatives (e.g., siblings, uncles, or aunts), (5) friends, (6) neighbors, (7) colleagues, (8) people known through voluntary activities, (9) in-laws (parents, sons, or daughters-in-law), and (10) members of their social group (e.g., community, congregation, sports, or music clubs). Higher total scores indicate greater social connectedness. |
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
General health status
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Short Form 12 Health Survey (SF-12) (12 Items, Items rated 0-1, 1-3 and 1-5 and 1-6 scores represent eight dimensions of physical and mental well-beeing with two composite scores, items are recodet, z-transformed and normed, higher values indicate better health)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Social Anxiety
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Social Phobia Inventory (SPIN) (17 Items, each item rated 0-4 points, minimum 0 points, maximum 68 points, higher scores indicate greater severity of social anxiety, three subscales are available (fear 6 items, avoidance 7 items, physiological distress 4 items))
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Somatic Symptom Burden
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
13-Item Somatic Symptom Severity Scale of the Patient Health Questionnaire (PHQ-13) (13 Items, each item rated 0-2 points, minimum 0 points, maximum 34 points, higher values indicating more somatic symptoms)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood markers (metabolic, LDL)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
LDL cholesterin [mg/dl or mmol/l], higher values (> 100 mg/dl or > 2.6 mmol/l) represent unfavorable metabolic risk
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (metabolic, HDL)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
HDL cholesterin [mg/dl or mmol/l), < 40 mg/dl men and < 50 mg/dl women represents unfavorable metabolic risk, ≥ 40 mg/dl men ≥ 50 mg/dl women acceptable, ≥ 60 mg/dl protective
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (metabolic, HbA1c)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
HbA1c [%], higher values (> 5.7%) represent unfavorable metabolic risk
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (Sphingolipid metabolism)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Sphingolipid metabolism enzyme activity of secretory acid sphingomyelinase (S-ASM) [nmol/mL/h/µL], higher leveles represent more inflammation/apoptosis enzyme activity of neutral acid sphingomyelinase (N-ASM) [nmol/mL/h/µL], higher levels represent cellular stress/apotosis Ceramide [nmol/L], higher levels represent more inflammation/apoptosis
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (neutrotrophic factor, BDNF)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
brain-derived neurotrophic factor [ng/mL], higher levels represent more neuroplasticity
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (hormonal)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Cortisol [µg/dL or nmol/L] and timepoint of blood test higher levels represent more stress response
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Blood markers (immunological markers)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
C-reactive protein (CRP) [mg/L], higher levels show systemic inflammation
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Saliva marker (cortisol)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
saliva cortisol (awakening and before bedtime), higher levels represent more stress response
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Saliva marker (α-amylase)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
saliva α-amylase activity [U/ml] (awakening and before bedtime), higher levels represent more stress response
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Stool markers
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
alpha-diversity
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Suicidality (clinician rated)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
measures in clinical interview (Montgomery-Åsberg Depression Rating Scale (MADRS)) (Item No. 10 out of 10 items, rated 0-6, higher values represent more suicidality)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Suicidality (self-report)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
9-Item Patient Health Questionnaire (PHQ-9) (Item No. 9 out of 9, rated 0-3 with higher scores indicating more suicidality)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
Response (depression)
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7) to T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks).
|
≥ 50% reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score from T0 to T1 (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7) to T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks).
|
|
Relapse (depression)
Tidsramme: T1 (end of inpatient stay/discharge from clinic ± 7 d) to Follow-Up/T2 (three months after clinical discharge ± 7 d).
|
≥ 10 points more from T1 to T2 in Montgomery-Åsberg Depression Rating Scale (MADRS) score or ≥ 22 points at T2 (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)
|
T1 (end of inpatient stay/discharge from clinic ± 7 d) to Follow-Up/T2 (three months after clinical discharge ± 7 d).
|
|
Antidepressant medication
Tidsramme: Baseline/T0 (normally day 1 of inpatient stay and maximum of day 2), T1 (end of inpatient stay, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
consideration of these classes of antidepressant drugs if these are given in a dosage that is effective as an antidepressant (e.g. for Mirtazapin not 7.5 mg, starting from 15 mg): SSRI/SNRI/NaSSA(Mirtazapin)/NDRI (Buproprion)/TZA/MAO-I/SARI (Trazodon)Agomelatin/other with classes of augmentation strategy: Lithium/antipsychotics/second antidepressant/other augmentation strategy sorted as: antidepressant monotherapy/antidepressant augmented therapy/other and change in therapy stategy (1.
no; 2. yes drug substance (2.1) added/ (2.2) changed/ (2.3) removed; 3. yes dosage of antidepressant changed (3.1) increased/(3.2) decreased; 4. augmentation strategy changed)
|
Baseline/T0 (normally day 1 of inpatient stay and maximum of day 2), T1 (end of inpatient stay, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
trait vs. state loneliness
Tidsramme: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
Given the absence of an established measure capable of differentiating between enduring (trait) and situational (state) loneliness, this aspect is captured by using a newly developed single item: 'In looking back upon my life, I would say that I have felt …'.
Participants respond to this item on a four-point scale (1= mostly lonely throughout my life, 2= lonely from time to time, 3= only lonely at present, and 4= never lonely).
Responses of 1 are intended to represent trait loneliness; options 2 and 3 represent state loneliness; and option 4 indicates no loneliness.
|
Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
|
|
number of therapies participated
Tidsramme: Baseline/T0 (normally day 1 of inpatient stay and maximum of day 2) to T1 (end of inpatient stay, normally 7 days up to 50 weeks).
|
frequency per week of psychotherapy, group interventions and other
|
Baseline/T0 (normally day 1 of inpatient stay and maximum of day 2) to T1 (end of inpatient stay, normally 7 days up to 50 weeks).
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Franziska Sonnauer, Dr. med., M.Sc., Department of Psychiatry and Psychotherapy, Friedrich-Alexander Universität Erlangen-Nürnberg
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 25-435-B
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .